<DOC>
	<DOCNO>NCT02372318</DOCNO>
	<brief_summary>The aim study use functional Magnetic Resonance Imaging ( fMRI ) measure neural reactivity alcohol-related emotional cue alcohol dependent subject follow single dose opioid receptor modulator nalmefene . The study do cross design nalmefene versus placebo .</brief_summary>
	<brief_title>Single-dose Nalmefene Modulate Neural Alcohol Cue Reactivity</brief_title>
	<detailed_description>All subject undergo battery minimal risk procedure study visit ; fill questionnaire , perform agree behavioral task , scan procedure include two functional MRI ( fMRI ) scan well structural MRI . The fMRI obtain non-abstinent participant breath alcohol concentration large &gt; 0.3 ‰ withdrawal severity 4 clinical institute withdrawal assessment alcohol ( CIWA-Ar ) scale . Alcohol consumption assess Form90 interview . Severity alcohol dependence examine Alcohol Dependence Scale ( ADS ) . Drinking situation assess Inventory Drinking Situations ( IDS ) . Trait aspects crave alcohol measure Obsessive Compulsive Drinking Scale ( OCDS ) . To examine state trait anxiety State-Trait Anxiety Inventory ( STAI ) use . Depressive symptom measure Beck Depression Inventory ( BDI ) State-Trait Depression Scales ( STDS ) . Nicotine consumption assess Fagerström Test Nicotine Dependence . The following scale administer fMRI scanning : The Alcohol Craving Questionnaire ( ACQ ) , Alcohol Urge Questionaire ( AUQ ) visual analogue scale crave assessment . Participants undergo two fMRI scan session interval one week : one 2 h administration nalmefene one 2 h administration placebo , carry randomized order . MRI examination include - cue-reactivity task ; - emotional face task ; - resting-state fMRI ; - structural MRI ; - include preparation , instruction break</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Nalmefene</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>severe alcohol use disorder accord DSM 5 `` heavy drinking '' : alcohol consumption &gt; =60g ( men ) &gt; =40g ( woman ) ( minimum 5 day / week ) righthandedness normal correct normal vision sign write informed consent valid time MRI investigation : psychotropic medication within last 14 day severe withdrawal symptom ( CIWAAr &gt; 4 ; Sullivan et al . 1989 ) intoxication ( breath alcohol concentration &gt; 0.3 ‰ ) common exclusion criterion MRI ( e.g . metal , claustrophobia ) positive drug screening ( opioids , cannabinoids , benzodiazepine , barbiturate , cocaine , amphetamine ) pregnancy contraindication prescription nalmefene valid inclusion : previous severe withdrawal / withdrawal complication previous inpatient detoxification treatment Axis I psychiatric diagnosis alcohol nicotinedependence last 12 month neurological disorder , history brain injury</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>opiod receptor modulator nalmefene</keyword>
	<keyword>cue-reactivity</keyword>
	<keyword>fMRI</keyword>
	<keyword>resting-state network</keyword>
</DOC>